Free Trial
NASDAQ:LPCN

Lipocine Q3 2024 Earnings Report

Lipocine logo
$3.41 -0.15 (-4.21%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$3.47 +0.06 (+1.88%)
As of 05/2/2025 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lipocine EPS Results

Actual EPS
-$0.44
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lipocine Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lipocine Announcement Details

Quarter
Q3 2024
Time
N/A
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Lipocine's Q1 2025 earnings is scheduled for Wednesday, May 7, 2025, with a conference call scheduled at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Lipocine Earnings Headlines

StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…
See More Lipocine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lipocine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lipocine and other key companies, straight to your email.

About Lipocine

Lipocine (NASDAQ:LPCN), a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

View Lipocine Profile

More Earnings Resources from MarketBeat